ascopubs.org

Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.

Targeting a non-canonical STING signaling pathway in T cells to improve antitumor immunity. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...
ascopubs.org

First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.

A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I ...
GEN

Metastatic Cancers Eliminated by CD40 Agonistic Antibody

Over the past 20 years, a class of anticancer drugs called CD40 agonist antibodies has shown great promise but also induced great disappointment. While such drugs have been effective at activating the ...
Animal Welfare Institute

Rommers, J. M., Reuvekamp, B. J. F., Gunnink, H. et al. 2014. Effect of hiding places, straw and territory on aggression in group-housed rabbit does. Applied Animal Behaviour ...

Group-housing of rabbit does may be preferred from welfare point of view. However, group-housing causes agonistic behaviour which may cause severe injuries. Severe injuries may be prevented by ...